![](https://www.mcknights.com/wp-content/uploads/sites/5/2021/10/GettyImages-1201491512-860x484.jpg)
Novo Nordisk Inc. announced it will pay $26.7 million to settle a pair of whistleblower cases related to marketing practices. The cases allege efforts to promote off-label uses of the anti-bleeding medication NovoSeven for unapproved indications, the company said.